Spyre Therapeutics CEO sells 15,000 shares

Spyre Therapeutics, Inc. (SYRE) Chief Executive Officer Cameron Turtle reported selling 15,000 shares of common stock on October 1, 2026, in six transactions under a Rule 10b5-1 trading plan adopted June 20, 2025.

Filing Impact

(Very High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. (SYRE) Chief Executive Officer Cameron Turtle reported selling 15,000 shares of common stock on October 1, 2026, in six transactions under a Rule 10b5-1 trading plan adopted June 20, 2025. Reported per-share prices were $89.1400, $90.1000, $91.4900, $92.3100, $93.3700 and $93.9100; the first five were weighted averages.

Insights

Analyzing...

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 6 txns

Insider Turtle Cameron

Role Chief Executive Officer

Sold 15,000 shs ($1.38M)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2, F3}	600	$89.14	$53K
Sale	Common Stock ^{F1, F4, F3}	2,683	$90.10	$242K
Sale	Common Stock ^{F1, F5, F3}	2,638	$91.49	$241K
Sale	Common Stock ^{F1, F6, F3}	3,989	$92.31	$368K
Sale	Common Stock ^{F1, F7, F3}	4,990	$93.37	$466K
Sale	Common Stock ^{F1, F3}	100	$93.91	$9K

Holdings After Transaction: Common Stock — 537,540 shares (Direct)

Footnotes (7)

F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F3. Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.80 to $90.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.85 to $91.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.87 to $92.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 15,000 shares Weighted average sale price: $89.1400 per share Weighted average sale price: $90.1000 per share +4 more

7 metrics

Shares sold 15,000 shares Six transactions on October 1, 2026

Weighted average sale price $89.1400 per share 600-share transaction on October 1, 2026

Weighted average sale price $90.1000 per share 2,683-share transaction on October 1, 2026

Weighted average sale price $91.4900 per share 2,638-share transaction on October 1, 2026

Weighted average sale price $92.3100 per share 3,989-share transaction on October 1, 2026

Weighted average sale price $93.3700 per share 4,990-share transaction on October 1, 2026

Sale price $93.9100 per share 100-share transaction on October 1, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, vest in monthly installments

3 terms

Rule 10b5-1 trading plan regulatory

"executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vest in monthly installments financial

"shares of common stock that vest in monthly installments through November 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SYRE shares did Cameron Turtle sell, and at what prices?

Spyre Therapeutics Chief Executive Officer Cameron Turtle reported selling 15,000 shares on October 1, 2026, under a Rule 10b5-1 plan adopted June 20, 2025. The six reported per-share prices were $89.1400, $90.1000, $91.4900, $92.3100, $93.3700 and $93.9100; the first five were weighted averages.

What price ranges were reported for Cameron Turtle's SYRE sales?

For the 600-, 2,683-, 2,638-, 3,989- and 4,990-share transactions, reported execution ranges were $88.63–$89.52, $89.80–$90.76, $90.85–$91.84, $91.87–$92.86 and $92.89–$93.80 per share, respectively. Another 100 shares were reported at $93.9100 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/02/2026 - 09:30 PM Accepted by SEC EDGAR 10/02/2026 - 09:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turtle Cameron

(Last)

(First)

(Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		S⁽¹⁾		600	D	$89.14⁽²⁾	551,940⁽³⁾	D
Common Stock	10/01/2026		S⁽¹⁾		2,683	D	$90.1⁽⁴⁾	549,257⁽³⁾	D
Common Stock	10/01/2026		S⁽¹⁾		2,638	D	$91.49⁽⁵⁾	546,619⁽³⁾	D
Common Stock	10/01/2026		S⁽¹⁾		3,989	D	$92.31⁽⁶⁾	542,630⁽³⁾	D
Common Stock	10/01/2026		S⁽¹⁾		4,990	D	$93.37⁽⁷⁾	537,640⁽³⁾	D
Common Stock	10/01/2026		S⁽¹⁾		100	D	$93.91	537,540⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.80 to $90.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.85 to $91.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.87 to $92.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR